Sign up to save your podcasts
Or
Share NAFLD: what your patients need to know | With Prof. William Alazawi
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
NAFLD: what your patients need to know | With Prof. William Alazawi
Non-alcoholic fatty liver disease (NAFLD) a condition where disruptions and dysregulation of lipids in the body causes an excessive build-up of fat in the liver, and is estimated to affect 75% of people with type 2 diabetes. In around 1/5 of cases this steatosis causes chronic inflammation, which can lead to fibrosis, cirrhosis and hepatocellular carcinoma. So what do people with diabetes need to know, and how do we raise awareness? We’re joined by Prof. William Alazawi to discuss these questions.
References:
Marjot T, et al. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020 Jan 1;41(1):bnz009. doi: 10.1210/endrev/bnz009.
Disclosures: Prof William Alazawi declares the following:
Speaker and Consulting: Gilead Sciences, Intercept, GSK, Coherus
Competitive grants: GSK, Gilead Sciences
All conflicts of interest have been mitigated prior to this activity.
Target Audience
This educational activity is intended for an international audience of non-US and non-UK HCPs.
Funding
This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.
View all episodes
By Liberum IME
5
11 ratings
Non-alcoholic fatty liver disease (NAFLD) a condition where disruptions and dysregulation of lipids in the body causes an excessive build-up of fat in the liver, and is estimated to affect 75% of people with type 2 diabetes. In around 1/5 of cases this steatosis causes chronic inflammation, which can lead to fibrosis, cirrhosis and hepatocellular carcinoma. So what do people with diabetes need to know, and how do we raise awareness? We’re joined by Prof. William Alazawi to discuss these questions.
References:
Marjot T, et al. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020 Jan 1;41(1):bnz009. doi: 10.1210/endrev/bnz009.
Disclosures: Prof William Alazawi declares the following:
Speaker and Consulting: Gilead Sciences, Intercept, GSK, Coherus
Competitive grants: GSK, Gilead Sciences
All conflicts of interest have been mitigated prior to this activity.
Target Audience
This educational activity is intended for an international audience of non-US and non-UK HCPs.
Funding
This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.